Skip to main content
Elsevier

Books in Neuropharmacology

Focusing on drug mechanisms, development, and therapeutic targets in the nervous system, this portfolio supports pharmacologists, neuroscientists, and clinicians. It features innovations in neurodrug delivery, receptor modulation, and treatment of neurological and psychiatric conditions.

  • Neuropsychopharmacology: A Tribute to Joseph T. Coyle

    • 1st Edition
    • Volume 76
    • English
    Neuropsychopharmacol... A Tribute to Joseph T. Coyle is a new volume from Advances in Pharmacology presenting reviews of recent breakthroughs in glutamate pharmacology and a tribute to one of the most influential neuroscientists of our times. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists, and biochemists alike.

  • Developing Therapeutics for Alzheimer's Disease

    Progress and Challenges
    • 1st Edition
    • Michael S. Wolfe
    • English
    Developing Therapeutics for Alzheimer's Disease: Progress and Challenges provides a thorough overview of the latest advances toward the development of therapeutics for Alzheimer’s disease, along with the major hurdles that still must be overcome and potential solutions to these problems. Despite the lack of progress toward developing therapeutics that can slow or stop the progression of this disease, important discoveries have been made and many promising approaches are advancing in preclinical studies and clinical trials. This book outlines the special challenges related to specific targets and approaches, while presenting a realistic, comprehensive and balanced view of drug discovery and development in this area. Written by international leaders in the field, the book assesses prospects for the emergence of effective agents and allows readers to better understand the challenges, failures, and future potential for research in Alzheimer’s disease. This book is a valuable resource to academic scientists carrying out translational research in Alzheimer’s disease, industrial scientists engaged in Alzheimer's drug discovery, executives in biopharmaceutical companies making strategic decisions regarding the direction of internal research and potential outside partnerships, and graduate-level students pursuing courses on Alzheimer's therapeutics.

  • Pharmacological Mechanisms and the Modulation of Pain

    • 1st Edition
    • Volume 75
    • English
    Pharmacological Mechanisms and the Modulation of Pain, the newest volume in the Advances in Pharmacology series, presents the pharmacological mechanisms and the modulation of pain. With a variety of chapters and the best authors in the field, this volume is an essential resource for pharmacologists, immunologists, and biochemists alike.

  • Drug Design and Discovery in Alzheimer’s Disease

    • 1st Edition
    • Atta-ur Rahman + 1 more
    • English
    Drug Design and Discovery in Alzheimer’s Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of β-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery.

  • The Neuropsychiatric Complications of Stimulant Abuse

    • 1st Edition
    • Volume 120
    • English
    This well-established international series examines major areas of basic and clinical research within neuroscience, as well as emerging and promising subfields. This volume concentrates on the neuropsychiatric complications of stimulant abuse.

  • TRP Channels as Therapeutic Targets

    From Basic Science to Clinical Use
    • 1st Edition
    • Arpad Szallasi
    • English
    TRP Channels as Therapeutic Targets: From Basic Science to Clinical Use is authored by experts across academia and industry, providing readers with a complete picture of the therapeutic potential and challenges associated with using TRP channels as drug targets. This book offers a unique clinical approach by covering compounds that target TRP channels in pre-clinical and clinical phases, also offering a discussion of TRP channels as biomarkers. An entire section is devoted to the novel and innovative uses of these channels across a variety of diseases, offering strategies that can be used to overcome the adverse effects of first generation TRPV1 antagonists. Intended for all researchers and clinicians working toward the development of successful drugs targeting TRP channels, this book is an essential resource chocked full of the latest clinical data and findings.

  • Global Clinical Trials for Alzheimer's Disease

    Design, Implementation, and Standardization
    • 1st Edition
    • Menghis Bairu + 1 more
    • English
    Global Clinical Trials for Alzheimer’s Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important considerations that may arise during the successful design and execution of these trials, including site selection, local regulatory issues, pharmacogenomics, ethical matters and much more. Given the saturation of traditional clinical trial markets and the worldwide progression of Alzheimer’s disease, there is a need to focus on clinical trials in emerging markets and developing countries. This book provides you with a practical approach to recognizing the opportunities and tackling the challenges that are present during the planning and execution of global clinical trials for Alzheimer’s disease.

  • Novel Psychoactive Substances

    Classification, Pharmacology and Toxicology
    • 1st Edition
    • Paul I. Dargan + 1 more
    • English
    Novel Psychoactive Substances: Classification, Pharmacology and Toxicology provides readers with background on the classification, detection, supply and availability of novel psychoactive substances, otherwise known as "legal highs." This book also covers individual classes of novel psychoactive substances that have recently emerged onto the recreational drug scene and provides an overview of the pharmacology of the substance followed by a discussion of the acute and chronic harm or toxicity associated with the substance. Written by international experts in the field, this multi-authored book is a valuable reference for scientists, clinicians, academics, and regulatory and law enforcement professionals.

  • Pathophysiology, Pharmacology and Biochemistry of Dyskinesia

    • 1st Edition
    • Volume 98
    • English
    Published since 1959, International Review of Neurobiology is a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. Led by an internationally renowned editorial board, this important serial publishes both eclectic volumes made up of timely reviews and thematic volumes that focus on recent progress in a specific area of neurobiology research. This volume reviews existing theories and current research surrounding the movement disorder Dyskinesia.

  • Pharmacology of 5-HT6 receptors, Part II

    • 1st Edition
    • Volume 96
    • English
    The serotonin 5-HT6 receptor represents a novel pharmacological target whose impact on physiopathology of CNS functions remains undetermined. Some receptor antagonists have been synthesized, and they show a modulatory role in learning and memory processes and food intake. The pharmacology of 5-HT6 receptor agonists is still under evaluation. However, both 5-HT6 antagonists and agonists seem to exert potential antidepressant activity. Recently, a second messenger system has been discovered. 5-HT6 receptor function is becoming more and more intriguing. Thus, the aim of the present book is to try to clarify the pharmacology of 5-HT6 receptors.